Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to -$32.5 million.

  • TScan Therapeutics' Cash from Operations fell 1628.34% to -$32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$130.7 million, marking a year-over-year decrease of 2197.6%. This contributed to the annual value of -$110.8 million for FY2024, which is 8061.54% down from last year.
  • Latest data reveals that TScan Therapeutics reported Cash from Operations of -$32.5 million as of Q3 2025, which was down 1628.34% from -$33.3 million recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Cash from Operations peaked at $8.0 million during Q3 2023, and registered a low of -$37.6 million during Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$22.0 million (2023), whereas its average is -$20.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 14715.33% in 2023, then plummeted by 44823.5% in 2024.
  • TScan Therapeutics' Cash from Operations (Quarter) stood at -$14.4 million in 2021, then fell by 11.34% to -$16.0 million in 2022, then tumbled by 48.44% to -$23.8 million in 2023, then fell by 15.34% to -$27.4 million in 2024, then dropped by 18.43% to -$32.5 million in 2025.
  • Its Cash from Operations was -$32.5 million in Q3 2025, compared to -$33.3 million in Q2 2025 and -$37.6 million in Q1 2025.